As a result of increasing competition, a smaller player (in the biosimilar field) is seeking to sell its nascent biosimilar business.
As a result of increasing competition, a smaller player (in the biosimilar field) is seeking to sell its nascent biosimilar business. Merck KGaA (which operates in the US as EMD Serono and is not associated with Merck & Company) has engaged the services of the investment banker JP Morgan Chase to seek potential buyers for its biosimilar unit.
Merck KGaA has decided to fortify its pipeline efforts instead on multiple sclerosis, where it has a strong marketing position with its product Rebif®, and in several cancer therapeutic approaches. The company’s only late-stage biosimilar is adalimumab (MSB11022), which is currently involved in a phase 3 trial with 400 patients that is supposed to be completed by September 2017. The primary endpoint results are slated to be available, however, in December 2016.
According to the announcement, the company’s biosimilars business could be valued at as much as $1 billion, not only based on its adalimumab agent but several undisclosed early-stage biosimilars. However, Merck may not make a big splash with its key product, as Amgen’s adalimumab has already been approved, and it may be one of several biosimilar versions to hit the market in the next few years, pending clearance of patent litigation.
In other news…Active biosimilar player Celltrion, from South Korea, has announced its submission of an application to the European Medicines Agency to license its version of Herceptin®. Interestingly, although it is approved for use in South Korea under the brand name Herzuma®, this biosimilar only commenced phase 1 trials in the US in September for eventual application to the Food and Drug Administration. No timetable has been announced for US submission.
Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings
May 16th 2024Two posters from the Academy of Managed Care Pharmacy’s annual meeting provided hope that despite low uptake so far, adalimumab biosimilars can deliver on the promise of comparable safety and efficacy with the originator in multiple disease states, as well as cost savings.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
Patients With IBD Experience Nocebo Effect Post Mandatory Switch to Biosimilar
May 11th 2024In Canada, a study on patients with inflammatory bowel disease (IBD) switching to infliximab or adalimumab biosimilars found no change in clinical remission or antidrug antibodies after 24 weeks, but 13% experienced the nocebo effect, leading to one-fifth discontinuing therapy.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.